中信建投证券股份有限公司 关于浙江仙琚制药股份有限公司 2023年度募集资金存放与使用情况的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为浙江仙琚制药股份有限公司（以下简称"仙琚制药"、"公司"）2020年度 非公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所股票上市规则》及《深圳证券交易所上市公司自律监管指引第13号—— 保荐业务》等有关规定，对仙琚制药2023年度募集资金存放与使用情况进行了核 查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准浙江仙 琚制药股份有限公司非公开发行股票的批复》（证监许可〔2020〕2217 号）核准， 浙江仙琚制药股份有限公司（以下简称"公司"）非公开发行人民币普通股股票 （A 股）72,992,700 股，每股面值 1 元，发行价格为 13.70 元/股，募集资金总额 为人民币 999,999,990 元，扣除相关发行费用后，实际募集资金净额为人民币 987,357,806.75 元。天健会计师事务所（特殊普通合伙）已 ...

浙江仙琚制药股份有限公司 2023 年度监事会工作报告 2023 年度，浙江仙琚制药股份有限公司（以下简称"公司"）监事会按照 《公司法》、《深圳证券交易所股票上市规则》、《公司章程》、《监事会议事 规则》等相关法律法规和公司规章制度的规定及要求，认真履行职责，依法行使 职权，对公司定期报告、生产经营活动、财务状况和公司董事、高级管理人员的 履职情况进行监督，促进了公司规范运作和健康发展。现将监事会 2023 年度的 主要工作报告如下： 一、监事会会议情况 2023 年度，公司监事会共召开了三次会议。会议的召集、召开符合《公司 法》、 《公司章程》等有关规定。监事会会议召开情况具体如下： 1、公司第八届监事会第二次会议于 2023 年 4 月 24 日在公司会议室召开， 本次会议审议并一致通过了以下议案： （7）《关于续聘天健会计师事务所（特殊普通合伙）为公司 2023 年度审计 机构的议案》； （8）《公司 2023 年第一季度报告》； （9）《关于 2023 年度日常关联交易预计的议案》； （10）《关于拟投资设立参股公司暨关联交易的议案》； （11）《浙江仙琚制药股份有限公司未来三年（2024-2026 ...

浙江仙琚制药股份有限公司 独立董事2023年度述职报告 本人（刘斌）作为浙江仙琚制药股份有限公司(以下简称"公司")第八届董 事会的独立董事，在 2023 年度严格按照相关法律法规的规定和要求，勤勉、忠 实、尽责地履行独立董事职责，维护公司整体利益和全体股东尤其是中小股东的 合法权益，现就 2023 年度履职情况述职如下： 一、出席董事会及股东大会情况 1、出席董事会会议情况 2023 年度，公司召开董事会 5 次，本人均亲自参加，无缺席情况。 对于上述会议，本人在会议召开前根据公司会议通知上所列的审议事项，主 动搜集获取对作出决议所需的资料和信息，在董事会上认真审议每个议案并积极 参与讨论，本着勤勉、尽责和诚信、负责的原则，对董事会所有议案进行了认真 思考后投了赞成票，没有投反对票和弃权票的情况。 2、出席股东大会情况 2023 年度，公司共召开了 1 次股东大会（即 2022 年度股东大会），本人亲 自参加，未有缺席情况。 二、发表独立意见情况 2023 年度，按照《独立董事工作制度》的要求，本人认真、勤勉、 尽责地 履行职责，在了解情况并查询相关文件后，发表的独立意见如下： （一）2023 年 4 月 ...

浙江仙琚制药股份有限公司 董事会审计委员会工作条例 浙江仙琚制药股份有限公司 董事会审计委员会工作条例 第一章 总则 第一条 为强化浙江仙琚制药股份有限公司(以下简称"公司")董事会决策功能，做 到事前审计、专业审计，确保董事会对经理层的有效监督，完善公司治理结构，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号一一主板上市公司规范运作》《上市公司独立 董事管理办法》等相关法律法规和《浙江仙琚制药股份有限公司章程》的要求，公司设立 董事会审计委员会，并制定本工作条例。 第二条 董事会审计委员会是董事会下设的专门委员会，主要负责公司内、外部审计 的沟通、监督和核查工作。 第二章 人员组成 第三条 审计委员会成员由 5 名不在公司担任高级管理人员的董事组成, 其中 3 名为 独立董事, 其中必须有 1 名为会计专业人士。审计委员会的召集人应当为担任独立董事的 会计专业人士。审计委员会成员应当具备履行审计委员会工作职责的专业知识和经验。审 计委员会成员应当勤勉尽责, 切实有效地监督、评估公司内外部审计工作, 促进公司建立 有效的内部 ...

内部控制审计报告 目 录 一、内部控制审计报告…………………………………………第 1—2 页 天健审〔2024〕2989 号 浙江仙琚制药股份有限公司全体股东： 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，仙琚制药公司于 2023 年 12 月 31 日按照《企业内部控制基本规 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江仙琚制药股份有限公司（以下简称仙琚制药公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是仙琚 制药公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 1,037,926,735.62, representing an increase of 8.42% compared to CNY 957,286,011.96 in the same period last year[5] - Net profit attributable to shareholders was CNY 151,121,862.92, up 13.53% from CNY 133,111,920.61 year-on-year[5] - Net profit for Q1 2024 was ¥156,516,313.26, representing a 21.0% increase from ¥129,297,563.51 in Q1 2023[19] - Basic and diluted earnings per share were both ¥0.15, compared to ¥0.13 in the previous year[20] - The company reported a total comprehensive income of ¥126,343,444.31, down from ¥143,736,260.16 in the same period last year[20] Cash Flow - The net cash flow from operating activities increased by 57.63%, reaching CNY 109,025,001.56 compared to CNY 69,164,061.26 in the previous year[5] - Cash inflow from operating activities totaled ¥825,567,894.71, an increase from ¥787,694,437.80 in the same quarter last year[21] - The net cash flow from operating activities for Q1 2024 was ¥109,025,001.56, an increase from ¥69,164,061.26 in Q1 2023, reflecting a growth of approximately 57.7%[22] - The net cash flow from investing activities was -¥63,759,854.47, compared to -¥33,293,931.92 in the previous year, indicating a decline of about 91.1%[22] - The net cash flow from financing activities was -¥15,199,172.59, which is a decrease from -¥12,503,725.80 in Q1 2023, representing a decline of approximately 21.6%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,186,668,564.94, reflecting a 2.77% increase from CNY 6,992,835,052.50 at the end of the previous year[5] - Current assets totaled CNY 3,521,007,668.76, up from CNY 3,399,871,398.68 at the start of the quarter, reflecting a growth of approximately 3.5%[15] - Total liabilities reached CNY 1,120,244,305.77, compared to CNY 1,046,909,543.49 at the beginning of the quarter, marking an increase of about 7%[15] - Total liabilities increased to ¥1,230,279,347.20, up from ¥1,162,789,279.07 year-on-year[19] - The total non-current assets amounted to CNY 3,665,660,896.18, up from CNY 3,592,963,653.82, reflecting an increase of approximately 2%[15] Research and Development - R&D expenses rose by 65.73%, amounting to an increase of CNY 27,170,900, primarily due to increased investment in research and development[8] - Research and development expenses rose to ¥68,506,786.98, a significant increase of 65.7% from ¥41,335,925.30 in Q1 2023[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,710[10] - Total equity attributable to shareholders reached ¥5,907,070,224.20, compared to ¥5,786,121,230.23 in the previous year[19] Other Income and Expenses - Other income increased by 206.7%, with an increase of CNY 3,812,100, mainly due to additional government subsidies received[8] - Operating costs amounted to ¥872,354,424.50, up 9.8% from ¥794,203,612.80 year-on-year[17] - Other comprehensive income after tax was negative at ¥-30,172,868.95, contrasting with a positive ¥14,438,696.65 in Q1 2023[19] Cash and Cash Equivalents - The company's cash and cash equivalents stood at CNY 1,667,358,088.81, slightly up from CNY 1,660,043,552.04, showing a marginal increase[14] - The total cash and cash equivalents at the end of Q1 2024 amounted to ¥1,644,145,718.81, down from ¥1,739,153,167.09 at the end of Q1 2023[22] Miscellaneous - The company reported a 100% increase in cash received from investment, totaling CNY 16,000,000, attributed to equity transfer payments received during the period[8] - The company experienced a 130.78% increase in contract liabilities, amounting to an increase of CNY 40,970,400, due to increased pre-receipts of sales[8] - The company did not undergo an audit for the Q1 2024 report[23] - The report was released by the chairman, Zhang Yusong, on April 25, 2024[23]

浙江仙琚制药股份有限公司 第八届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2024年4月23日，浙江仙琚制药股份有限公司（以下简称"公司"）第八届 监事会第五次会议在公司会议室以现场方式召开，会议通知及会议资料已于2024 年4月12日以电子邮件方式送达全体监事。会议由公司监事会主席吴天飞先生召 集和主持，会议应到监事7人，实到监事7人，董事会秘书和证券事务代表列席了 会议，会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有关 规定。与会监事以现场投票表决方式通过了以下决议： 一、以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023年度 监事会工作报告》。该议案尚需提交2023年年度股东大会审议。 《2023年度监事会工作报告》具体内容详见2024年4月25日的巨潮资讯网 （www.cninfo.com.cn）。 二、以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《公司2023 年度财务决算报告》。该议案尚需提交2023年年度股东大会审议。 2023 年度公司财务数据业经天健会计师事务所( ...

证券代码：002332 证券简称：仙琚制药 公告编号：2024-022 浙江仙琚制药股份有限公司 关于2023年度利润分配预案的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2024年4月23日召开第 八届董事会第九次会议和第八届监事会第五次会议，审议通过了《公司2023年 度利润分配预案》，该议案尚需提交2023年度股东大会审议。现将具体情况公 告如下： 一、2023年度利润分配预案的基本情况 经天健会计师事务所（特殊普通合伙）审计，公司 2023 年度归属于上市公 司股东的净利润为 563,083,493.15 元，按母公司实现的净利润提取 10%法定盈 余公积金 38,005,460.46 元，加上年初未分配利润 1,669,615,779.59 元，减去 分配 2023 年度现金股利 296,761,459.80 元，公司期末可供股东分配的利润为 1,714,903,463.88 元。现公司拟以 2023 年 12 月 31 日总股本 989,204,866 股为 基数，每 10 股派发现金股利 3 ...

Financial Performance - In 2023, the company achieved operating revenue of CNY 4,123.42 million, a year-on-year decrease of 5.85%[23]. - The net profit attributable to shareholders was CNY 563.08 million, down 24.86% compared to the previous year[23]. - The weighted average return on net assets was 10.06%[23]. - The net profit after deducting non-recurring gains and losses was CNY 537,526,425.95, reflecting a 12.14% decrease from the previous year[138]. - The basic earnings per share for 2023 was CNY 0.57, a decline of 24.76% compared to the previous year[138]. - The company experienced its first annual decline in operating performance since 2015, attributed to the impact of centralized procurement and intensified competition in the raw material drug market, leading to a decrease in sales prices[80]. - The company reported a non-operating income of ¥25,557,067.20, significantly lower than the previous year's figure of ¥137,609,898.48[124]. - The company’s operating revenue for 2023 was CNY 4,123,418,584.19, a decrease of 5.85% compared to the previous year[138]. Revenue Segmentation - The total revenue for the raw materials segment reached ¥1,786,178,433.68, representing a year-on-year increase of 26.21%[41]. - The formulation segment generated revenue of ¥2,278,091,400.81, with a year-on-year growth of 73.24%[41]. - The total revenue from other segments amounted to ¥15,188,752.85, reflecting a year-on-year increase of 72.01%[41]. - The revenue from formulation sales was 2.278 billion yuan, down 12.4%, while the self-operated formulation sales revenue was 2.109 billion yuan, down 15%[186]. - The revenue from raw materials and intermediates was 1.786 billion yuan, an increase of 3%, with self-operated raw material sales revenue at 880 million yuan, up 10%[186]. - Domestic sales decreased by 9.06% to approximately $2.94 billion, accounting for 71.41% of total revenue[200]. - International sales increased by 3.25% to approximately $1.18 billion, representing 28.59% of total revenue[200]. Investment and R&D - The company reported a significant increase in investment, with a total of CNY 66.32 million, representing a 194.75% increase year-on-year[22]. - Research and development expenses totaled ¥260,996,011.23, accounting for 6.33% of total revenue, an increase from 6.09% in the previous year[52]. - The company has multiple ongoing R&D projects aimed at expanding its gynecological and reproductive product lines, with several projects (C012, C013, C083, C093, C095, C106, C107, C108, C109) in the process of obtaining drug approvals[56]. - The company has established an open R&D platform with multiple subsidiaries, enhancing its R&D capabilities in complex formulations and active pharmaceutical ingredients[181]. - The company has made significant progress in product registration, with 13 projects entering clinical trials and 11 projects in the review stage[196]. - The company completed new product or consistency evaluation applications for six products, including Dydrogesterone tablets, and received approvals for three new products during the reporting period[159]. Compliance and Quality Management - The company successfully passed the FDA inspection with a "zero defect" rating, marking a significant milestone in quality management[27]. - The company maintains strict compliance with GMP standards throughout its production processes to ensure product quality and safety[154]. - The raw material drug manufacturing facility successfully passed certifications from the US FDA, WHO, and Japan, laying the groundwork for future expansion into high-end markets[80]. Market Strategy and Operations - The company is focusing on internationalization and improving compliance management to enhance product quality and market competitiveness[27]. - The company has established a three-segment sales model focusing on self-operated sales teams, local distributors, and e-commerce channels[155]. - The company is committed to a market-oriented approach to enhance operational efficiency and product quality, fostering a unique corporate culture centered on craftsmanship[76]. - The company is enhancing its sales capabilities and digital operations, focusing on specialized academic promotion for new products and improving the sales system to ensure long-term sustainable growth[171]. - The company aims to enhance its market response speed and customer service capabilities through a three-line linkage mechanism in research, production, and sales, while also exploring new markets and customer opportunities[174]. Financial Management - The net cash flow from operating activities was ¥595,482,358.68, a decrease of 2.27% compared to the previous year[55]. - The total cash inflow from investment activities dropped by 93.75% to ¥54,341,332.57, primarily due to the absence of structured deposit redemptions this period[55]. - The total cash outflow from financing activities decreased by 37.17% to ¥465,225,230.83, mainly due to reduced loan repayments and increased dividend distributions[55]. - The company has a significant amount of short-term loans, which decreased from 37,398,657.51 yuan to 1,030,807.61 yuan, indicating improved debt management[66]. - The company has committed to repay bank loans totaling CNY 18 million, with 100% of the funds allocated for this purpose already utilized[94]. Corporate Recognition and Achievements - The company received multiple accolades, including being named one of the "Top 100 Pharmaceutical Companies in China" and recognized as a "National Enterprise Technology Center" by the National Development and Reform Commission[77]. - The company has received verification of the raised funds from Tianjian Accounting Firm, confirming the amount raised and its usage[92]. - The company achieved a silver medal rating of 59 points in EcoVadisd, reflecting its commitment to corporate social responsibility[199].

公司外汇套期保值业务是以规避汇率风险为目的，不投机，不进行单纯以盈 利为目的的外汇交易。 二、外汇套期保值业务期间、业务规模及投入资金 关于继续开展外汇套期保值业务的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2024年4月23日召开第 八届董事会第九次会议，审议通过了《关于继续开展外汇套期保值业务的议案》， 同意公司在本次董事会审议通过之日起12个月内开展任意时点累计金额不超过 2000万美元或等值外币的外汇套期保值业务。现将相关情况公告如下： 一、公司开展外汇套期保值业务的目的 由于公司原料药及有关产品自营出口收入在公司营业总收入中占比较大，主 要采用美元、欧元等外币进行结算，当汇率出现较大波动时，汇兑损益对公司的 经营业绩会造成较大影响。为了降低汇率波动对公司利润的影响，公司拟与银行 等金融机构开展外汇套期保值业务，包括远期结售汇交易、人民币与外汇掉期交 易、人民币对外汇期权组合业务等，通过锁定远期结售汇汇率及汇率区间，在人 民币兑外币汇率双向波动的情况下，减少对公司营业利润的影响。 证券代码：00 ...